Arvaya Healthcare Limited completes acquisition of 100% equity of SIGPL
Bijoy Hans · Commercial Services & Supplies
Key highlights
- Acquired 1,84,374 equity shares constituting 100% of Sushodha Institute of Gastroenterology Private Limited
- Acquisition completed on 1st November 2026
- SIGPL is now a wholly-owned subsidiary of Arvaya Healthcare Limited from 1st November 2026
Why it's rated notable: The filing completes the acquisition of 100% of SIGPL but states no consideration amount, so the event cannot be sized against the stated market value of ₹543 crore and stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Fine Organic Industries Ltd announces Q2 and H1 FY27 financial results and acquisitions
- Lloyds Metals and Energy Limited announces Q2 FY 2026-27 results and approves investments
- Kotak Mahindra Bank receives CCI approval for Deutsche Bank India business acquisition
- Endurance Technologies reports Q2 and H1 FY27 financial results with growth
- Prestige Estates Projects acquires 100% of Gloind Vintage Infra via PRVL
- Systematic Industries approves half-year results and allots 14,57,400 preferential shares
Potential multibaggers · Q2 FY27
Potential multibaggers in Commercial Services & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.